Premier Path Wealth Partners LLC Acquires 3,561 Shares of Pfizer Inc. $PFE

Premier Path Wealth Partners LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,160 shares of the biopharmaceutical company’s stock after buying an additional 3,561 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Pfizer were worth $1,628,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter valued at $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the first quarter valued at approximately $28,000. North Capital Inc. purchased a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $24.32 on Thursday. The company has a market cap of $138.26 billion, a PE ratio of 12.94, a P/E/G ratio of 0.81 and a beta of 0.55. The firm’s 50 day moving average price is $24.82 and its 200-day moving average price is $24.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.